. . , significantly (19.2%; p < 0.0;) d u r i n i th; first 12 h of PT. After discontinuation of PT, CBFV as well as RBFV values returned to baseline values. LVO and mean PBFV lncreased significantly 2 1 2 h of PT: 26.3%; p<0.05 and 22.6%; p<0.01 respectively. LVO as well as mean PBFV remained at higher levels after the withdrawal of PT than they had been before the onset of PT. It appeared that 9 of the 18 infants developed PDA durina PT. These lnfants had a sianificantlv hiaher mean PBFV > 12 h of PT than Pre-. --the infantsaithout PDA had.
use; thrombocytopenia may be a side effect.
A 20 DIFFICULTIES IN D I A G N O S I S OF S E C O N D A R Y LEUKEMIA IN P A T I E N T S T R E A T E D F O R A C U T E L Y M P H O B L A S T I C LEUKEMIA
Auke 6eishuizen1 Elisabet R van wering2 Karel ~~h l e n ' .~ Marie-Anne J. V6rhoevenpand Jacques ~. h . Despite major improvements in the treatment of acute lymphoblastic leukemia (ALL) patients during the last two decades. 20.30% of children with ALL still relapse. In 5.10% of these relapses a secondary leukemia is diagnosed. Most secondary leukemias are myeloid in origin and only 5.10% are lymphoid.
Fourty ALL patients were analyzed for their cytomorphology, immunophenotype and immunogenotype at diagnosis and relapse. lmmunogenotypic studies included the analysis of immunoglobulin heavy chain (IgH). Igx. I@. T-cell receptor-8 (TcR-p). TcR-y, and TcR-6 genes. In two precursor 6-ALL cases an interlineage shift to acute myeloid leukemia (AML) occurred. suggesting the development of a secondary leukemia. In one of them, a complete change in immunogenotype at relapse was found, supporting the diagnosis of secondary leukemia. However, in the other case, seven identically rearranged IgH and TcR alleles were still present at relapse, indicating that the AML was related to the precursor B-ALL at diagnosis and thereby excluding the development of a secondary leukemia. In a third precursor B-ALL, the immunophenotype at diagnosis and relapse was identical, but a completely different immunogenotype (on at least ten lg and TcR alleles) was found at relapse, suggesting a secondary ALL. Unfortunately, no cytogenetic data at diagnosis and relapse were ava~lable for confirmation of this assumption.
These three cases demonstrate the difficulties in defining a secondary leukemia based on cytomorphology and immunophenotype and emphasize the importance of immunogenetic studies a s well a s cytogenetic analysis of malignant cell samples to determ~ne the clonal relation or clonal evolution between d~agnosis and relapse. Previous studies showed an early increase in systemic vascular resistance and a decrease in the perfusion of brain, kidneys and intestines for at least 2 h. The effect of Indo on cardiopulmonary hemodynamics was studied in 14 preterm infants. PDA was diagnosed clinically and confirmed by echo~ardiograph~. We measured LV-output (mL/mL.min;' kg-') and the resistance in the ascending aona (RAO; mmHg/mL.min." kg') before Indo and during the first 12 h after a single i.v. dose 0.1 mg/kg at 1 h, 4 h and 12 h. T o assess changes in ductal patency and postductal pulmonary flow we measured peak velocities at the ductalpulmonary opening (D-PV) and in the left pulmonary anery (P-PV) in m.sec'. Results: All 14 infants had clinical signs of PDA at 1 h after Indo, this number was reduced to 9 at 4 h after Indo but in only 1 infant ductus closure was definite. Measurements are summarized in the 
ARE THERE CHANGES I N CARDIO-PULMONARY HEMODYNAMICS AFIXR
Boston. MA; Kosalr CH, ~o i s v i l l e , KY: CHHC-San Dieqo. Ca. USA.
-.
At 6 centers. 306 lnfants wlth slgniflcant lung d~s e a s e were randomized at 7.5 i 6 hrs of a g e to SlMV or IMV. SlMV was performed with the Infantstar ventilator and Star Sync module. lnfants on each mode had similar BW. GA. Apgar scores, arterial-alveolar oxygen (a/A) ratio at time of random~zat~on. # surfactant doses and rates of sepsis and PDA. The rates of mortality. IVH and pharmacologic paralys~s were s~milar. The median duration (95% confidence ~ntewal) of mechanical ventilation of survivors was:
In infants with BW < 1 kg, the need for supplemental 0, at 35 weeks corrected age was less for SlMV (46%) than IMV (77%), p c 0.05 In Infants with BW 1-2 kg there was more rapid improvement on SlMV with lower average Fro, and higher a/A ratlo during the first 12 hours (p < 0 05). and a trend for less sedalion with benzodiazepines (p = 0.08) and morph~ne (p = 0 1) dur~ng the f~rsl 10 days In ~nfants with BW > 2 kg, there were trends toward decreased pneumothorax occurrence and need for ECMO on SlMV (both p = 0.1). SlMV compared lo IMV In s~c k newborns can improve oxygenation, shorten the duration of ventilat~on and reduce chron~c lung d~sease. 
